Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920
05 11월 2024 - 11:27PM
Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq:
TVGN), a clinical-stage specialty immunotherapy biotech developing
off-the-shelf, genetically unmodified T cell therapeutics to treat
infectious disease and cancers, recently announced its Artificial
Intelligence effort, Tevogen.AI, had partnered with Microsoft
(Nasdaq: MSFT), the world’s leading AI company.
Using Microsoft’s suite of advanced tools, Tevogen Bio is
proactively investigating potential treatments for HPV to create a
portfolio of oncology products. The company has developed a dataset
of proteins from the HPV genome and is identifying cytotoxic T cell
(CTL) targets to choose for a clinical trial for TVGN 920, its
first oncology product. Through Tevogen’s proprietary ExacTcell™
technology, where CTLs are trained to detect specific targets and
then expanded, the company aims to be prepared to deliver an
HPV-specific CTL treatment.
“Our ExacTcell technology, which has proven effective in
developing SARS-CoV-2-specific CTLs, can be rapidly adapted to
create CTL products targeting a wide range of viruses, including
HPV,” said Dr. Neal Flomenberg, Chief Scientific Officer at Tevogen
Bio. “While the specific targets may vary between viruses, the
platform itself is well-established, enabling a swift response to
emerging infectious threats.”
“By leveraging Microsoft’s cutting-edge AI and cloud
technologies, we’re able to accelerate our target identification
and pre-clinical processes in ways that weren’t previously
possible,” said Mittul Mehta, Chief Information Officer and Head of
Tevogen.AI. “Our partnership is allowing us to automate critical
steps in the development pipeline, enhancing our readiness to
quickly address additional indications, such as HPV.”
"With national healthcare cost and patient affordability at the
forefront of our presidential candidates’ agendas, the urgency is
clear,” commented Ryan Saadi, Founder and CEO, Tevogen Bio. “In
2023, U.S. healthcare spending reached an astounding $4.8 trillion
- 17.6% of GDP - highlighting the potential impact on economic
prosperity. As the new administration charts its course, Tevogen
looks forward to being part of a sustainable solution."
About Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy company
harnessing CD8+ cytotoxic T lymphocytes, to develop off-the-shelf,
genetically unmodified T cell therapeutics to treat infectious
disease and cancers, aiming to address the significant unmet needs
of large patient populations. Tevogen leadership believes that
sustainability and commercial success in the current era of
healthcare rely on ensuring patient accessibility through advanced
science and innovative business models. Tevogen has reported
positive safety data from its proof-of-concept clinical trial, and
its key intellectual property assets are wholly owned by the
company, not subject to any third-party licensing agreements. These
assets include three granted patents and numerous pending patents,
two of which are related to artificial intelligence.
Tevogen is driven by a team of experienced industry leaders and
scientists with drug development and global product launch
experience. Tevogen’s leadership believes that accessible
personalized therapeutics are the next frontier of medicine, and
that disruptive business models are required to sustain medical
innovation.
Forward Looking Statements
This press release contains certain forward-looking statements,
including without limitation statements relating to: expectations
regarding the healthcare and biopharmaceutical industries;
Tevogen’s development of, the potential benefits of, and patient
access to its product candidates for the treatment of infectious
diseases, cancer and neurological disorders, including TVGN 489 for
the treatment of COVID-19 and Long COVID; Tevogen’s ability to
develop additional product candidates, including through use of
Tevogen’s ExacTcell platform; the anticipated benefits of
ExacTcell; expectations regarding Tevogen’s future clinical trials;
and Tevogen’s ability to generate revenue in the future.
Forward-looking statements can sometimes be identified by words
such as “may,” “could,” “would,” “expect,” “anticipate,”
“possible,” “potential,” “goal,” “opportunity,” “project,”
“believe,” “future,” and similar words and expressions or their
opposites. These statements are based on management’s expectations,
assumptions, estimates, projections and beliefs as of the date of
this press release and are subject to a number of factors that
involve known and unknown risks, delays, uncertainties and other
factors not under the company’s control that may cause actual
results, performance or achievements of the company to be
materially different from the results, performance or other
expectations expressed or implied by these forward-looking
statements.
Factors that could cause actual results, performance, or
achievements to differ from those expressed or implied by
forward-looking statements include, but are not limited to: that
Tevogen will need to raise additional capital to execute its
business plan, which may not be available on acceptable terms or at
all; the effect of the recent business combination with Semper
Paratus Acquisition Corporation (the “Business Combination”) on
Tevogen’s business relationships, operating results, and business
generally; the outcome of any legal proceedings that may be
instituted against Tevogen related to the Business Combination;
changes in the markets in which Tevogen competes, including with
respect to its competitive landscape, technology evolution, or
regulatory changes; changes in domestic and global general economic
conditions; the risk that Tevogen may not be able to execute its
growth strategies or may experience difficulties in managing its
growth and expanding operations; the risk that Tevogen may not be
able to develop and maintain effective internal controls; costs
related to the Business Combination and the failure to realize
anticipated benefits of the Business Combination; the failure to
achieve Tevogen’s commercialization and development plans, and
identify and realize additional opportunities, which may be
affected by, among other things, competition, the ability of
Tevogen to grow and manage growth economically and hire and retain
key employees; the risk that Tevogen may fail to keep pace with
rapid technological developments to provide new and innovative
products and services or make substantial investments in
unsuccessful new products and services; the ability to develop,
license or acquire new therapeutics; that Tevogen will need to
raise additional capital to execute its business plan, which may
not be available on acceptable terms or at all; the risk of
regulatory lawsuits or proceedings relating to Tevogen’s business;
uncertainties inherent in the execution, cost, and completion of
preclinical studies and clinical trials; risks related to
regulatory review, and approval and commercial development; risks
associated with intellectual property protection; Tevogen’s limited
operating history; and those factors discussed or incorporated by
reference in Tevogen’s Annual Report on Form 10-K and subsequent
filings with the SEC.
You should not place undue reliance on forward-looking
statements, which speak only as of the date they are made. Tevogen
undertakes no obligation to update any forward-looking statements,
except as required by applicable law.
Contacts
Tevogen Bio CommunicationsT: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
Tevogen Bio (NASDAQ:TVGN)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Tevogen Bio (NASDAQ:TVGN)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024